PLK1-IN-10 (30, 50 mg/kg; i.p.; every two days for 32 days) significantly inhibits tumor growth in A549/DDP drug-resistant xenograft mice, with the 50 mg/kg group even causing tumor regression[1].
PLK1-IN-10 (30 mg/kg; p.o.; every two days for 20 days) effectively inhibits tumor growth in NCI-H1975 drug-resistant xenograft mice[1].
| Animal Model: | A549/DDP drug-resistant xenograft mice[1] |
| Dosage: | 30, 50 mg/kg |
| Administration: | i.p.; once every two days for 32 days |
| Result: | TGI reached 42% for the 30 mg/kg group and 62% for the 50 mg/kg group.
Extended the median survival time from 38 days in the control group to 53 days in the 30 mg/kg group and 62 days in the 50 mg/kg group.
Had no significant impact on the body weight and major organs of the mice, except for a slight difference in heart index observed in the 30 mg/kg group.
Significantly reduced the number of Ki-67 positive cells in the tumor tissue.
Showed no significant differences in H&E staining of major organs, further confirming its good biosafety. |
| Animal Model: | NCI-H1975 drug-resistant xenograft mice[1] |
| Dosage: | 30 mg/kg |
| Administration: | p.o.; once every two days for 20 days |
| Result: | TGI reached 44%. Caused no harm to the body weight and major organs of the mice. |
